In ₹ Crore except Per Share Latest Annual | MANKIND FY26 | SUNPHARMA FY26 | CIPLA FY26 | TORNTPHARM FY26 | Peer Median | |
|---|---|---|---|---|---|---|
| Valuation — at last close | ||||||
| P/E | 48.46× | 38.70× | ◆ 28.61× | 77.05× | 38.70× +25% | |
| P/B | 5.60× | 5.29× | ◆ 3.22× | 9.48× | 5.29× +6% | |
| EV/EBITDA | 26.84× | 23.53× | ◆ 17.43× | 39.37× | 23.53× +14% | |
| Market Cap | ₹92,715 Cr | ₹4.44L Cr | ₹1.11L Cr | ₹1.67L Cr | ₹1.67L Cr -44% | |
| Growth | ||||||
| Revenue CAGR 3Y | ◆ 17.73% | 10.03% | 7.37% | 13.27% | 10.03% +77% | |
| Revenue CAGR 5Y | — | 11.78% | 8.01% | ◆ 11.80% | 11.78% | |
| Net Income CAGR 3Y | 13.96% | 10.57% | 10.88% | ◆ 19.75% | 10.88% +28% | |
| Revenue YoY (latest Q) | 12.89% | 10.46% | 2.33% | ◆ 54.85% | 10.46% +23% | |
| Net Income YoY (latest Q) | ◆ 29.12% | 26.53% | -39.18% | 3.28% | 3.28% +788% | |
| Profitability | ||||||
| EBITDA Margin | 25.34% | 30.33% | 20.89% | ◆ 32.61% | 30.33% -16% | |
| Net Income Margin | 13.57% | ◆ 19.69% | 13.71% | 15.29% | 15.29% -11% | |
| Return on Common Equity | 11.55% | ◆ 13.69% | 11.24% | 12.30% | 12.30% -6% | |
| Return on Capital Employed | 12.66% | ◆ 17.17% | 13.17% | 9.56% | 13.17% -4% | |
| Return on Assets | 6.90% | ◆ 10.58% | 9.09% | 4.82% | 9.09% -24% | |
| Credit & Quality | ||||||
| Total Debt/Equity | 0.38× | 0.05× | ◆ 0.01× | 0.84× | 0.05× +660% | |
| Interest Coverage | 4.27× | 43.65× | ◆ 85.90× | 8.94× | 43.65× -90% | |
| Scale — latest FY | ||||||
| Revenue / Total Income | ₹14,278 Cr | ₹58,462 Cr | ₹28,163 Cr | ₹13,980 Cr | ₹28,163 Cr -49% | |
| Net Income | ₹1,938 Cr | ₹11,509 Cr | ₹3,862 Cr | ₹2,138 Cr | ₹3,862 Cr -50% | |
| Total Assets | ₹28,080 Cr | ₹1.09L Cr | ₹42,496 Cr | ₹44,312 Cr | ₹44,312 Cr -37% | |
| EPS | ₹46.35 | ₹47.8 | ₹48.03 | ₹63.92 | ₹48.03 -3% | |
| Book Value per Share | ₹401.19 | ₹349.6 | ₹427.34 | ₹519.56 | ₹427.34 -6% | |